



FDA U.S. FOOD & DRUG
ADMINISTRATION

FY 2024

Real Time Report

pursuant to the

Federal Food, Drug, and Cosmetic Act

as amended by the Generic Drug User Fee Amendments of 2022

Acronyms

FD&C Act – Federal Food, Drug, and Cosmetic Act

FDA – Food and Drug Administration

FDAUFRA 2022 – FDA User Fee Reauthorization Act of 2022

FY – Fiscal Year (October 1 to September 30)

GDUFA – Generic Drug User Fee Amendments

Q1 – Quarter 1 (October 1 to December 31)

Q2 – Quarter 2 (January 1 to March 31)

Q3 – Quarter 3 (April 1 to June 30)

Q4 – Quarter 4 (July 1 to September 30)

Background

On September 30, 2022, the FDA User Fee Reauthorization Act of 2022 (FDAUFRA) (Division F of Public Law 117-180) was signed into law. FDAUFRA 2022 amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) by revising and extending the user fee programs for human prescription drugs, biologics, generic drugs, medical devices, and biosimilar biological products.

Section 744C(a)(2) of the FD&C Act requires the Food and Drug Administration (FDA) to provide “Real Time” reporting, posted on a quarterly basis, of guidance documents and public meetings related to human generic drug activities.¹

Real Time Reporting Under Section 744C(a)(2) of the FD&C Act

This report is being issued pursuant to the requirement of Section 744C(a)(2) of the FD&C Act, which states:

“Not later than 30 calendar days after the end of each quarter of each fiscal year for which fees are collected under this part, the Secretary [of Health and Human Services] shall post...on the internet website of the Food and Drug Administration...

- “The number and titles of draft and final guidance on topics related to human generic drug activities and whether such guidances were issued as required by statute or pursuant to a commitment under the letters described in section 301(b) of the Generic Drug User Fee Amendments of 2022.”
- “The number and titles of public meetings held on topics related to human generic drug activities and whether such meetings were required by statute or pursuant to a commitment under the letters described in section 301(b) of the Generic Drug User Fee Amendments of 2022.”

¹ This report provides information related to human generic drug activities, which are defined by section 744A(9) of the FD&C Act as specified activities associated with generic drugs and inspection of facilities associated with generic drugs. This report does not include information regarding biosimilar biologic license applications, which is presented in the ‘Real Time’ report pursuant to the Biosimilar User Fee Act.

Human Generic Drugs

Guidance Documents

Pursuant to Section 744C(a)(2) of the FD&C Act, the table below lists the number and titles of draft and final guidances on topics related to human generic drug activities and whether such guidances were issued as required by statute or pursuant to a commitment under the letters described in section 301(b) of the Generic Drug User Fee Amendments of 2022. Guidances are listed by the quarter in which they were issued and are provided in a cumulative format for Fiscal Year (FY) 2024.

Table 1: Draft and Final Guidance Documents Related to the Human Generic Drug Activities for FY 2024

Number	Quarter Issued	Title & Website Link	Date Issued	Issued as Required by Statute or Pursuant to Commitment Letter	Statutory or Commitment Letter Citation (if applicable)
1	Q1	Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities; Draft Guidance for Industry www.fda.gov/media/173286/download	10/26/2023	Other	N/A
2	Q1	Albuterol Sulfate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020503.pdf	11/16/2023	Other	N/A
3	Q1	Azacitidine; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214120.pdf	11/16/2023	Other	N/A
4	Q1	Betamethasone Acetate; Betamethasone Sodium Phosphate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_014602.pdf	11/16/2023	Other	N/A
5	Q1	Budesonide; Formoterol Fumarate Dihydrate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021929.pdf	11/16/2023	Other	N/A
6	Q1	Chlorhexidine Gluconate; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017768.pdf	11/16/2023	Other	N/A
7	Q1	Cimetidine; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017920.pdf	11/16/2023	Other	N/A
8	Q1	Citalopram Hydrobromide; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215428.pdf	11/16/2023	Other	N/A
9	Q1	Deucravacitinib; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214958.pdf	11/16/2023	Yes	Section III.C.1 of GDUFA II commitment letter.
10	Q1	Deutetrabenazine; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216354.pdf	11/16/2023	Other	N/A

Number	Quarter Issued	Title & Website Link	Date Issued	Issued as Required by Statute or Pursuant to Commitment Letter	Statutory or Commitment Letter Citation (if applicable)
11	Q1	Dextroamphetamine; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215401.pdf	11/16/2023	Other	N/A
12	Q1	Edaravone; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215446.pdf	11/16/2023	Other	N/A
13	Q1	Emtricitabine; Tenofovir Alafenamide Fumarate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208215.pdf	11/16/2023	Other	N/A
14	Q1	Ferric Pyrophosphate Citrate; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208551.pdf	11/16/2023	Other	N/A
15	Q1	Ferric Pyrophosphate Citrate; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206317.pdf	11/16/2023	Other	N/A
16	Q1	Ferric Pyrophosphate Citrate; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212860.pdf	11/16/2023	Other	N/A
17	Q1	Ferumoxytol; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022180.pdf	11/16/2023	Other	N/A
18	Q1	Fingolimod Lauryl Sulfate; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214962.pdf	11/16/2023	Other	N/A
19	Q1	Fluticasone Propionate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021433.pdf	11/16/2023	Other	N/A
20	Q1	Fluticasone Propionate; Salmeterol Xinafoate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021254.pdf	11/16/2023	Other	N/A
21	Q1	Fulvestrant; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021344.pdf	11/16/2023	Other	N/A
22	Q1	Furosemide; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209988.pdf	11/16/2023	Yes	Section III.C.2.c of GDUFA III Commitment Letter.
23	Q1	Futibatinib; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214801.pdf	11/16/2023	Yes	Section III.C.1 of GDUFA II commitment letter.
24	Q1	Gabapentin; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022544.pdf	11/16/2023	Other	N/A
25	Q1	Ganaxolone; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215904.pdf	11/16/2023	Yes	Section III.C.1 of GDUFA II commitment letter.
26	Q1	Glatiramer Acetate; Revised Draft Guidance for www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020622.pdf	11/16/2023	Other	N/A

Number	Quarter Issued	Title & Website Link	Date Issued	Issued as Required by Statute or Pursuant to Commitment Letter	Statutory or Commitment Letter Citation (if applicable)
27	Q1	Glycopyrrolate; Neostigmine Methylsulfate; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_216903.pdf	11/16/2023	Other	N/A
28	Q1	Halobetasol Propionate; Tazarotene; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_209354.pdf	11/16/2023	Other	N/A
29	Q1	Latanoprost; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_216472.pdf	11/16/2023	Other	N/A
30	Q1	Levalbuterol Tartrate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_021730.pdf	11/16/2023	Other	N/A
31	Q1	Mometasone Furoate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_205641.pdf	11/16/2023	Other	N/A
32	Q1	Naltrexone; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_021897.pdf	11/16/2023	Other	N/A
33	Q1	Omidinepag Isopropyl; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_215092.pdf	11/16/2023	Yes	Section III.C.1 of GDUFA II commitment letter.
34	Q1	Primidone; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_009170.pdf	11/16/2023	Other	N/A
35	Q1	Risperidone; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_210655.pdf	11/16/2023	Other	N/A
36	Q1	Semaglutide; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_215256.pdf	11/16/2023	Other	N/A
37	Q1	Semaglutide; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_209637.pdf	11/16/2023	Other	N/A
38	Q1	Sotorasib; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_214665.pdf	11/16/2023	Other	N/A
39	Q1	Soybean Oil; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_017643.pdf	11/16/2023	Other	N/A
40	Q1	Tapinarof; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_215272.pdf	11/16/2023	Other	N/A
41	Q1	Tiotropium Bromide; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_021395.pdf	11/16/2023	Other	N/A
42	Q1	Clindamycin Phosphate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_050600.pdf	11/21/2023	Other	N/A

Number	Quarter Issued	Title & Website Link	Date Issued	Issued as Required by Statute or Pursuant to Commitment Letter	Statutory or Commitment Letter Citation (if applicable)
43	Q1	Inclisiran Sodium; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214012.pdf	11/21/2023	Other	N/A
44	Q1	Ruxolitinib Phosphate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215309.pdf	11/21/2023	Other	N/A
45	Q1	Advanced Manufacturing Technologies Designation Program; Draft Guidance for Industry www.fda.gov/media/174651/download	12/13/2023	Other	N/A
46	Q1	Data Standards for Drug and Biological Product Submissions Containing Real-World Data; Final Guidance for Industry www.fda.gov/media/153341/download	12/22/2023	Other	N/A
47	Q1	Real-World Data: Assessing Registries To Support Regulatory Decision-Making for Drug and Biological Products; Final Guidance for Industry www.fda.gov/media/154449/download	12/22/2023	Other	N/A
48	Q1	Quality Considerations for Topical Ophthalmic Drug Products; Draft Guidance for Industry www.fda.gov/media/172937/download	12/27/2023	Other	N/A
49	Q1	Reformulating Drug Products That Contain Carbomers Manufactured With Benzene; Final Guidance for Industry www.fda.gov/media/175083/download	12/28/2023	Other	N/A
50	Q2	Requests for Reconsideration at the Division Level Under GDUFA; Draft Guidance for Industry www.fda.gov/media/108398/download	1/10/2024	Other	N/A
51	Q2	Revising ANDA Labeling Following Revision of the RLD Labeling; Final Guidance for Industry www.fda.gov/media/175654/download	1/24/2024	Other	N/A
52	Q2	ANDA Submissions – Amendments and Requests for Final Approval to Tentatively Approved ANDAs; Final Guidance for Industry www.fda.gov/media/119718/download	1/24/2024	Other	N/A
53	Q2	Abacavir Sulfate; Dolutegravir Sodium; Lamivudine; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215413.pdf	2/15/2024	Other	N/A
54	Q2	Aclidinium Bromide; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202450.pdf	2/15/2024	Other	N/A
55	Q2	Aclidinium Bromide; Formoterol Fumarate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_210595.pdf	2/15/2024	Other	N/A
56	Q2	Adagrasib; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216340.pdf	2/15/2024	Yes	Section III.C.2.c of GDUFA III Commitment Letter.
57	Q2	Albuterol Sulfate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_205636.pdf	2/15/2024	Other	N/A

Number	Quarter Issued	Title & Website Link	Date Issued	Issued as Required by Statute or Pursuant to Commitment Letter	Statutory or Commitment Letter Citation (if applicable)
58	Q2	Amoxicillin; Clarithromycin; Vonoprazan Fumarate; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215152.pdf	2/15/2024	Yes	Section III.C.1 of GDUFA II commitment letter.
59	Q2	Amoxicillin; Vonoprazan Fumarate; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215153.pdf	2/15/2024	Other	N/A
60	Q2	Aprepitant; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209296.pdf	2/15/2024	Other	N/A
61	Q2	Baclofen; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215422.pdf	2/15/2024	Other	N/A
62	Q2	Betamethasone Dipropionate; Clotrimazole; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020010.pdf	2/15/2024	Other	N/A
63	Q2	Betamethasone Dipropionate; Clotrimazole; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_018827.pdf	2/15/2024	Other	N/A
64	Q2	Budesonide; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021949.pdf	2/15/2024	Other	N/A
65	Q2	Budesonide; Formoterol Fumarate; Glycopyrrolate; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212122.pdf	2/15/2024	Other	N/A
66	Q2	Caffeine; Ergotamine Tartrate; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_086557.pdf	2/15/2024	Other	N/A
67	Q2	Dapsone; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207154.pdf	2/15/2024	Other	N/A
68	Q2	Dapsone; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021794.pdf	2/15/2024	Other	N/A
69	Q2	Dexamethasone; Neomycin Sulfate; Polymyxin B Sulfate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050023.pdf	2/15/2024	Other	N/A
70	Q2	Dexamethasone; Tobramycin; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050616.pdf	2/15/2024	Other	N/A
71	Q2	Dexamethasone; Tobramycin; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050592.pdf	2/15/2024	Other	N/A
72	Q2	Dexamethasone; Tobramycin; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050818.pdf	2/15/2024	Other	N/A

Number	Quarter Issued	Title & Website Link	Date Issued	Issued as Required by Statute or Pursuant to Commitment Letter	Statutory or Commitment Letter Citation (if applicable)
73	Q2	Diazepam; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_211635.pdf	2/15/2024	Other	N/A
74	Q2	Doxepin Hydrochloride; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202036.pdf	2/15/2024	Other	N/A
75	Q2	Durlobactam Sodium; Durlobactam Sodium; Sulbactam Sodium; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216974.pdf	2/15/2024	Yes	Section III.C.2.c of GDUFA III Commitment Letter.
76	Q2	Elagolix Sodium, Estradiol, Norethindrone Acetate; Elagolix Sodium; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213388.pdf	2/15/2024	Other	N/A
77	Q2	Ferric Carboxymaltose; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_203565.pdf	2/15/2024	Other	N/A
78	Q2	Ferric Derisomaltose; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208171.pdf	2/15/2024	Other	N/A
79	Q2	Finasteride; Tadalafil; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215423.pdf	2/15/2024	Other	N/A
80	Q2	Flutifolastat F-18 Gallium; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216023.pdf	2/15/2024	Yes	Section III.C.2.c of GDUFA III Commitment Letter.
81	Q2	Fluorometholone; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_016851.pdf	2/15/2024	Other	N/A
82	Q2	Fluticasone Furoate; Umeclidinium Bromide; Vilanterol Trifenatate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209482.pdf	2/15/2024	Other	N/A
83	Q2	Fluticasone Propionate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208798.pdf	2/15/2024	Other	N/A
84	Q2	Fluticasone Propionate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020833.pdf	2/15/2024	Other	N/A
85	Q2	Fluticasone Propionate; Salmeterol Xinafoate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021077.pdf	2/15/2024	Other	N/A
86	Q2	Fluticasone Propionate; Salmeterol Xinafoate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208799.pdf	2/15/2024	Other	N/A

Number	Quarter Issued	Title & Website Link	Date Issued	Issued as Required by Statute or Pursuant to Commitment Letter	Statutory or Commitment Letter Citation (if applicable)
87	Q2	Formoterol Fumarate; Glycopyrrolate; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208294.pdf	2/15/2024	Other	N/A
88	Q2	Hydrocortisone; Neomycin Sulfate; Polymyxin B Sulfate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_060613.pdf	2/15/2024	Other	N/A
89	Q2	Lenacapavir Sodium; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215974.pdf	2/15/2024	Yes	Section III.C.2.c of GDUFA III Commitment Letter.
90	Q2	Lenacapavir Sodium; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215973.pdf	2/15/2024	Yes	Section III.C.2.c of GDUFA III Commitment Letter.
91	Q2	Loteprednol Etabonate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020583.pdf	2/15/2024	Other	N/A
92	Q2	Loteprednol Etabonate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_200738.pdf	2/15/2024	Other	N/A
93	Q2	Loteprednol Etabonate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020803.pdf	2/15/2024	Other	N/A
94	Q2	Loteprednol Etabonate; Tobramycin; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_050804.pdf	2/15/2024	Other	N/A
95	Q2	Mannitol; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022368.pdf	2/15/2024	Other	N/A
96	Q2	Mannitol; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202049.pdf	2/15/2024	Other	N/A
97	Q2	Mometasone Furoate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021067.pdf	2/15/2024	Other	N/A
98	Q2	Naloxone Hydrochloride; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208969.pdf	2/15/2024	Yes	Section III.C.2.c of GDUFA III Commitment Letter.
99	Q2	Nilotinib Hydrochloride; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022068.pdf	2/15/2024	Other	N/A
100	Q2	Niraparib Tosylate; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214876.pdf	2/15/2024	Other	N/A
101	Q2	Olutasidenib; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215814.pdf	2/15/2024	Yes	Section III.C.2.c of GDUFA III Commitment Letter.

Number	Quarter Issued	Title & Website Link	Date Issued	Issued as Required by Statute or Pursuant to Commitment Letter	Statutory or Commitment Letter Citation (if applicable)
102	Q2	Rivaroxaban; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_215859.pdf	2/15/2024	Other	N/A
103	Q2	Salmeterol Xinafoate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_020692.pdf	2/15/2024	Other	N/A
104	Q2	Sertraline Hydrochloride; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_215133.pdf	2/15/2024	Other	N/A
105	Q2	Sodium Phenylbutyrate; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_214860.pdf	2/15/2024	Other	N/A
106	Q2	Sodium Phenylbutyrate; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_216513.pdf	2/15/2024	Other	N/A
107	Q2	Sodium Phenylbutyrate; Taurursodiol; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_216660.pdf	2/15/2024	Yes	Section III.C.1 of GDUFA II Commitment letter.
108	Q2	Terlipressin Acetate; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_022231.pdf	2/15/2024	Yes	Section III.C.1 of GDUFA II Commitment letter.
109	Q2	Testosterone Undecanoate; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_213953.pdf	2/15/2024	Other	N/A
110	Q2	Umeclidinium Bromide; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_205382.pdf	2/15/2024	Other	N/A
111	Q2	Umeclidinium Bromide; Vilanterol Trifenatate; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_203975.pdf	2/15/2024	Other	N/A
112	Q2	Vandetanib; Revised Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_022405.pdf	2/15/2024	Other	N/A
113	Q2	Xenon Xe-129 Hyperpolarized; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_214375.pdf	2/15/2024	Yes	Section III.C.2.c of GDUFA III Commitment Letter.
114	Q2	Zanamivir; Draft Guidance for Industry www.accessdata.fda.gov/drugsatfda_docs/psg/P SG_021036.pdf	2/15/2024	Other	N/A
115	Q2	Q2(R2) Validation of Analytical Procedures; Final Guidance for Industry www.fda.gov/media/161201/download	3/6/2024	Other	N/A
116	Q2	Q14 Analytical Procedure Development; Final Guidance for Industry www.fda.gov/media/161202/download	3/7/2024	Other	N/A

Number	Quarter Issued	Title & Website Link	Date Issued	Issued as Required by Statute or Pursuant to Commitment Letter	Statutory or Commitment Letter Citation (if applicable)
117	Q2	Annual Reportable Labeling Changes for New Drug Applications and Abbreviated New Drug Applications for Nonprescription Drug Products; Draft Guidance for Industry www.fda.gov/media/176915/download	3/13/2024	Other	N/A
118	Q2	Controlled Correspondence Related to Generic Drug Development; Final Guidance for Industry www.fda.gov/media/164111/download	3/18/2024	Other	N/A
119	Q2	Handling and Retention of Bioavailability BA and Bioequivalence BE Testing Samples; Draft Guidance for Industry www.fda.gov/media/71393/download	3/27/2024	Other	N/A

Public Meetings

Pursuant to section 744C(a)(2) of the FD&C Act, the table below lists the number and titles of public meetings held on topics related to human generic drug activities and whether such meetings were required by statute or pursuant to a commitment under the letters described in section 301(b) of the Generic Drug User Fee Amendments of 2022. Public meetings are listed by the quarter in which they were held and are provided in a cumulative format for FY 2024.

Table 2: Public Meetings Held on Topics Related to Human Generic Drug Activities for FY 2024

Number	Quarter Held	Title	Date Held	Held as Required by Statute or Pursuant to Commitment Letter
1	Q1	2023 NanoDay Symposium: Continuous Manufacturing of Nanomaterials www.fda.gov/drugs/news-events-human-drugs/2023-nanoday-symposium-continuous-manufacturing-nanomaterials-10112023	10/11/2023	No
2	Q1	FDA and Center for Research on Complex Generics Co-Hosted Workshop: Advances in PBPK Modeling and its Regulatory Utility for Oral Drug Product Development www.fda.gov/news-events/advances-pbpbk-modeling-and-its-regulatory-utility-oral-drug-product-development-10122023	10/12/2023	No
3	Q1	FDA CTTI Meeting on Mitigating Clinical Study Disruptions During Disasters and Public Health Emergencies www.fda.gov/drugs/news-events-human-drugs/fdactti-meeting-mitigating-clinical-study-disruptions-during-disasters-and-public-health-emergencies	10/18/2023-10/19/2023	FDORA 3605
4	Q1	Pharmaceutical Quality Symposium 2023: Quality, Supply Chain & Advanced Manufacturing	10/31/2023-11/1/2023	No

		www.fda.gov/drugs/news-events-human-drugs/pharmaceutical-quality-symposium-2023-quality-supply-chain-advanced-manufacturing-10312023		
5	Q1	Positron Emission Tomography: Product Quality Regulatory Submissions, Facility Inspections, and Benefit-Risk Considerations www.fda.gov/drugs/news-events-human-drugs/positron-emission-tomography-product-quality-regulatory-submissions-facility-inspections-and-benefit	11/13/2023-11/14/2023	No
6	Q1	FDA CTTI Public Workshop to Enhance Clinical Study Diversity www.fda.gov/drugs/news-events-human-drugs/discussing-approaches-enhance-clinical-study-diversity-public-workshop-11292023	11/29/2023-11/30/2023	FDORA 3603
7	Q1	FDA and Center for Research on Complex Generics Co-Hosted Workshop: Characterization of Complex Excipients and Formulations www.complexgenerics.org/education-training/characterization-of-complex-excipients-formulations/	12/07/2023	No
8	Q2	A Deep Dive: FDA's Model-Integrated Evidence (MIE) Industry Meeting Pilot Program for Generic Drugs www.fda.gov/drugs/news-events-human-drugs/deep-dive-fdas-model-integrated-evidence-mie-industry-meeting-pilot-program-generic-drugs-01182024	1/18/2024	No
9	Q2	Expanding Generic Drug Access Through International Engagements www.fda.gov/drugs/news-events-human-drugs/expanding-generic-drug-access-through-international-engagements-02282024	2/28/2024	No
10	Q2	Product Quality Research Institute (PQRI) Workshop: MIDD Approaches in Pediatric Formulation Development www.fda.gov/drugs/news-events-human-drugs/product-quality-research-institute-pqri-workshop-midd-approaches-pediatric-formulation-development	2/28/2024-2/29/2024	No
11	Q2	FDA and Center for Research on Complex Generics Co-Hosted Workshop: Drug-Device Combination Products: Updates and Challenges with Demonstrating Generic Substitutability www.complexgenerics.org/education-training/drug-device-combination-products-updates-and-challenges-with-demonstrating-generic-substitutability/	3/14/2024-3/15/2024	No